Abstract
The acute antidyskinetic effects of IV amantadine in HD were evaluated. A 2-hour IV infusion of amantadine or placebo was administered to nine patients with HD on two different days in a double-blind, randomized crossover fashion. All patients subsequently received oral amantadine unblinded for a 1-year period. A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Aged
-
Amantadine / administration & dosage
-
Amantadine / therapeutic use*
-
Cross-Over Studies
-
Drug Administration Schedule
-
Excitatory Amino Acid Antagonists / administration & dosage
-
Excitatory Amino Acid Antagonists / therapeutic use*
-
Female
-
Glutamic Acid / metabolism
-
Humans
-
Huntington Disease / drug therapy*
-
Huntington Disease / physiopathology
-
Huntington Disease / psychology
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Motor Activity / drug effects
-
Neuropsychological Tests
-
Severity of Illness Index
-
Treatment Outcome
Substances
-
Excitatory Amino Acid Antagonists
-
Glutamic Acid
-
Amantadine